



EuroISSHP

**European Congress of the
INTERNATIONAL SOCIETY
FOR THE STUDY OF
HYPERTENSION IN
PREGNANCY**

ROME, 5-7 October 2011

**National Research Council
Piazzale Aldo Moro**



**European Congress of the
INTERNATIONAL SOCIETY
FOR THE STUDY OF
HYPERTENSION IN
PREGNANCY**

Hosted by the
AIPE - Associazione Italiana Preeclampsia
Italian Branch of the ISSHP

Prof. ANDREA LUIGI TRANQUILLI
Prof. PANTALEO GRECO

Chairman of the Organizing Committee

Prof. HERBERT VALENSISE

Scientific secretariat:

Barbara Vasapollo

Gian Paolo Novelli (bgp.novelli@alice.it)

Organizing secretariat:

ALFA CONGRESSI srl

IT 00192 Rome - viale delle Milizie, 34

ph. +39063701121 r.a. - fax +39063729067

alfa@alfaservice.com - www.alfaservice.com

**AIPE PRECONGRESS COURSE
CLASSIFICAZIONE E TRATTAMENTO
DELLA PREECLAMPSIA**

- 8.00 Classificazione ipertensione-preeclampsia
N. Rizzo (Bologna, IT)
- 8.45 Screening della preeclampsia
A. Valcamonico (Brescia, IT)
- 9.30 Ipertensione gestazionale lieve
G. Simonazzi (Bologna, IT)
- 10.15 Gestione della preeclampsia lieve ed ipertensione lieve e moderata
L. Marozio (Torino, IT)
- 11.00 Gestione preeclampsia moderata e severa e ipertensione severa
S. Giannubilo (Ancona, IT)
- 11.45 Complicanze coagulative
S. Ferrazzani (Roma, IT)
- 12.30 Le complicanze neurologiche della preeclampsia e loro prevenzione
A. Lovotti (Como, IT)
- 13.15 Chiusura dei lavori

**EUROPEAN CONGRESS OF THE
INTERNATIONAL SOCIETY
FOR THE STUDY OF HYPERTENSION
IN PREGNANCY**

OPENING OF THE CONGRESS

- 14.00 PRESIDENTIAL ADDRESS
*A. Tranquilli (Ancona, IT), B. Sibai (Cincinnati, USA),
P. Greco (Foggia, IT), H. Valensise (Roma, IT)*
- 14.15 LECTURE:
Management of imitators of severe preeclampsia-eclampsia
B. Sibai (Cincinnati, USA)
- 14.45 LECTURE:
The Pathogenesis of pre-eclampsia: an overview
C. Redman (Oxford, UK)

PLACENTAL AND FETAL PREECLAMPSIA

- Chair:** *F. Lyall (Glasgow, UK), C. Redman (Oxford, UK)*
- 15.15 Placental preeclampsia
F. Lyall (Glasgow, UK)
- 15.45 Clinical utility of placental growth factor - pathological insights from commercial assays
C. Redman (Oxford, UK)
- 16.00 Placental inflammatory factors and preeclampsia
F. Petraglia (Siena, IT)

- 16.15 Genetic aspects of preeclampsia
L. Marozio (Torino, IT)
- 16.30 Placental oxygenation and respiration in preeclampsia
I. Cetin (Milano, IT)
- 16.45 Experimental models in preeclampsia
R. Napolitano, P. Martinelli (Napoli, IT)
- 17.15 Early, late, maternal, placental pre-eclampsia: which definition?
T. Todros (Torino, IT)
- 17.30 Evaluation of different model for the prediction of preeclampsia at the 1st trimester of pregnancy
A. Farina (Bologna, IT)
- 17.45 Comparison of two Placental Growth Factor Immunoassays as an aid in the diagnosis of preterm preeclampsia
R. North (London, UK)
- 18.00 Dramatic upregulation of HIF-1 α in the endovascular and extravillous trophoblast
L. Druzin (Stanford, USA)
- 18.10 The predominance of Th 17 lymphocytes and decreased number of function of Treg cells in preeclampsia
Daemochwal-Kolarz (Lubin, Pl - YIA)
- 18.20 Serum concentrations of angiogenic factors as predictors of severity of preeclampsia in Colombian population
M.C. Pãez (Bucaramanga, CO - YIA)
- 18.30 Predisposing factors for early and late preeclampsia
S. Ornaghi (Monza, IT - YIA)
- Session ends

PREDICTION AND PREVENTION OF PREECLAMPSIA

Chair: A. Khalil (London, UK), R. D'Anna (Messina, IT)

- 8.30 First trimester screening for preeclampsia
A. Khalil (London, UK)
- 9.00 NGAL, an early marker of endothelial dysfunction in preeclampsia
R. D'Anna (Messina, IT)
- 9.15 Prediction and prevention of preeclampsia in autoimmune disease
F. Mecacci (Firenze, IT)
- 9.30 New biophysical technologies for the prediction of placental ischemic hypoxic disease
E. Ferrazzi (Milano, IT)
- 9.45 Using biochemical markers of cardiac function to predict preeclampsia
S. Cecchi (Ancona, IT - YIA)
- 10.00 The role of heparin in the prevention of preeclampsia
S. Ferrazzani (Roma, IT)
- 10.15 sFlt-1/pLgf in preeclampsia
S. Verlohren (Berlin, D)
- 10.30 Low-dose aspirin therapy in pregnant women with chronic hypertension
E. Baptista (Coimbra, P - YIA)
- 10.40 Uterine artery Doppler in a risk population: what's its role in the prediction of small for gestational age fetuses
I. Cameroni (Monza, IT - YIA)
- 10.50 Prospective evaluation of ultrasound and biochemical based multivariable models for the prediction of late preeclampsia
G. Rapacchia (Bologna, IT)
- 11.00 Angiogenic factors combined with clinical risk factors to predict preterm preeclampsia in nulliparous women
J.E. Myers (Manchester, UK)
- 11.15 Coffee Break

DIABETES AND PREECLAMPSIA

Chair: M. Hod (Tel Aviv, IL), P. Greco (Foggia, IT)

- 11.30 Hapo study and preeclampsia
M. Hod (Tel Aviv, IL)
- 12.00 Inositol phosphoglycans in the pathophysiology of preeclampsia
M. Scioscia (Negrar, VR)
- 12.15 The role of glycemic control in the development of preeclampsia in type 1 diabetic woman
G. Mello, S. Ottanelli (Firenze, IT)
- 12.30 Diabetes and preeclampsia a walk through metabolic syndrome
S. Alberico (Trieste, IT)
- 12.45 Evaluating fetal cord blood lipids and oxidized LDL status in the intrauterine growth restriction and preeclampsia
U. Pecks (Aachen, G)

- 12.55 A obesity-related FTO variant and the risk of preeclampsia in a Finnish study population
M. Klemetti (Helsinki, FIN - YIA)
- 13.05 Myo-inositol may prevent metabolic and hypertensive disorders in PCOS pregnant women
R. D'Anna, M.L. Interdonato (Messina, IT)
- 13.15 Lunch break

POSTER SESSION 1

Discussant: A. Tranquilli (Ancona, IT), B. Sibai (Cincinnati, USA)

1. **Are components of the Renin Angiotensin System (RAS) associated with oxidative stress in normotensive (NT) and pre-eclamptic (PE) placentae?**
Kurlak LO, Mistry HD, Broughton Pipkin F (Nottingham, UK; London, UK)
2. **Targeted Gene Arrays across the Severely-Discordant growth Monochorionic Twin Placenta: Implications for Angiogenesis and Metabolic Programming**
Schrey S, Baczyk D, Fitzgerald B, Keating S, Ryan G, Kingdom J, Drewlo S (Toronto, Canada)
3. **The Effects of Statins and Antihypertensives on Placental secretion of Angiogenic Proteins in term Pre-eclampsia**
Gangooly, Jauniaux and Muttukrishna (London UK - Cork, Ireland)
4. **Placental Effects of Antihypertensives on Activin A and Inhibin A in Pre-eclampsia**
Gangooly, Hristova M, Jauniaux E and Muttukrishna S (London UK - Cork, Ireland)
5. **Uteroplacental arterio-venous difference in sFlt, but not in endoglin concentrations in preeclampsia**
Roland MCP, Lorentzen B, Godang K, Henriksen T. (Oslo, Norway)
6. **Bioinformatic analysis of protein-protein interaction network in preeclampsia**
E. Tejera, J Bernardes, I Rebelo (Porto, Portugal)
7. **Active and inactivated hemopexin in pregnancy and preeclampsia: do they activate monocytes and endothelial cells?**
F. Spaans, C. Chiang, W.W. Bakker, T. Borghuis, M.M. Faas (Groningen, The Netherlands)
8. **Role of EGF-like Domain 7 (Egfl7) in Placental Development and Implantation**
Silvia Salvi, Sergio Ferrazzani, Lucia Vecchione, Gregorio Siracusa, Heidi Stuhlmann and Luisa Campagnolo (Rome, Italy; New York, USA)
9. **Circulating ficolins in normal pregnancy and preeclampsia**
Molvarec A, Szarka A, Stenczer B, Szi-jártó J, Rigó J Jr. (Budapest, Hungary)
10. **The Elecsys Assay for PIGF, sFlt1 and their ratio (sFlt1/PIGF) as an aid in differential diagnosis of pregnancy-related hypertensive disorders**
Engels T, Pape J, Schoofs K, Denk B, Beinder E, Verlohren S (Berlin, Germany)
11. **Placental Expression of Haemostatic and Angiogenic Markers in Preeclampsia**
Lynne Kelly, Shanthi Muttukrishna, Lucy Norris and John Higgins (Cork, Ireland; Dublin, Ireland)
12. **Differentially expressed micro-RNAs in microparticles from haemoglobin perfused placentas**
T. Rasmussen, K. May, M. Familiari, S. Guller, H. Schneider, B. Åkerström, S.R. Hansson (Lund, Sweden; Greifswald, Germany; Melbourne, Australia; New Haven, Connecticut, USA; Bern, Switzerland)

13. **Placental gene expression analysis at the end of the first trimester of pregnancy in patients at high risk of subsequent development of preeclampsia**
Ulrik Dolberg Anderson, MD Baskaran Thilaganathan, Professor Stefan R Hansson, Professor (London, UK)
14. **Alterations in placental expression of Caveolin-1, Cavin-1 and eNOS in women with pre-eclampsia**
Kate Smith-Jackson, Anna N. Czajka, Lesia O. Kurlak, Fiona Broughton Pipkin, Rachel M. Tribe, Michael J. Taggart & Hiten D. Mistry (London, Nottingham, Newcastle, UK)
15. **The number and location of vessels with decidual vasculopathy correlate with disease severity in preeclampsia**
Droïma Stevens, BA, Salwan Al-Nasiry, MD, PhD, Hans Bulten, MD, PhD and Marc Spaanderman, MD, PhD (Nijmegen, The Netherlands)
16. **The influence of maternal Lewis, Secretor and ABO(H) blood groups on pre-eclampsia and fetal growth restriction**
Peter Clark and Olivia Wu (Glasgow, UK)
17. **Uterine Artery Doppler Ultrasonography And Pre-Eclampsia**
Raposo S, Carvalho MJ, Ferreira A, Campos S, Vasco E, Bento N, Pais MSJ, Jardim O, Moura P (Coimbra, Portugal)
18. **Significance of uteroplacental Doppler at midtrimester in low risk parous women**
Arcangeli Tiziana MD Giorgetta Francesca MD, Federica Bellussi MD, Francesca De Musso MD, Rizzo Nicola Professor; Ghi Tullio MD, PhD (Bologna, Italy)
19. **Angiogenic Factors For The Prediction Of Early- And Late Onset Preeclampsia In A High Risk Cohort**
Villa PM, Hamalainen E, Pesonen A, Raikkonen K, Taipale P, Kajantie E, Laivuori H (Helsinki, Finland)
20. **Comparing the Pregnancy Outcome in Nulliparas both with and without Microalbuminuria at the end of the second trimester of Pregnancy**
Maryam Kashanian MD, Shohreh Bahasadri MD, Zahra Khosravi MD (Tehran, Iran)
21. **Prediction of preterm preeclampsia by combining Histidine-Rich Glycoprotein and uterine artery Doppler in early pregnancy**
Marie Bolin, Anna-Karin Wikström, Eva Wiberg-Itzel, Inger Sundström-Poromaa, Ove Axelsson, Basky Thilaganathan and Helena Åkerud (Uppsala, Sundsvall, Sweden)
22. **Role of uterine artery doppler in pregnant women with chronic hypertension**
Moita B, Baptista E, Marques C, Bombas T, Bento N, Pais MSJ, Moura (Coimbra, Portugal)
23. **Evaluation Of A New, Simple And Rapid Placental Growth Factor Test For The Evaluation Of Hypertensive Disorders In Pregnancy**
Balázs Stenczer, MD; Attila Molvarec, MD, Ph.D.; Nóra Gullai, MD; Gergely Fügedi; Bálint Nagy, Ph.D., János Rigó Jr., MD, Ph.D., D.Sc. (Budapest, Hungary)
24. **Prediction of preeclampsia during early pregnancy in primiparas with soluble fms-like tyrosine kinase-1 and placental growth factor**
Dileep Kumar Rohra, Amna Zeb, Rahat Najam Qureshi, Syed Iqbal Azam, Neelofur Babar Khan, Hina Saeed Zuberi, Rozina Sikandar (Karachi, Pakistan; Riyadh, Kingdom of Saudi Arabia)
25. **Study of C677T methylene tetrahydrofolate reductase (mthfr) polymorphism in preeclampsia**
Andreia Matos, Joana Ferreira, Ana Portelinha, Ana Sofia Cerdeira, Jorge Braga, Belmiro Patrício, Irene Rebelo, Manuel Bicho, Claudia Marinho (Lisbon, Porto, Portugal)

26. **Increased inhibin a in severe preeclampsia/eclampsia**
Arisanti Y., Akbar MIA., Wicaksono B., Sulistyono A., Dachlan EG., Angsar MD.
(Surabaya, Indonesia)
27. **Comparison Serum Inhibin A Level, Placenta Inhibin A Level And Placenta Inhibin A Expression In Severe Preeclampsia / Eclampsia And Normal Pregnant Women**
Arisanti Y, Akbar MIA., Wicaksono B., Sulistyono A., Dachlan EG., Angsar MD.
(Surabaya, Indonesia)

CARDIOVASCULAR FUNCTION

- Chair:** M. G. Mohaupt (Bern, Switzerland), H. Valensise (Roma, IT)
- 14.30 The role of aldosterone in normal and preeclamptic pregnancies
M.G. Mohaupt (Bern, CH)
- 15.00 Total Vascular Resistance in complicated pregnancies
B. Vasapollo (Roma, IT)
- 15.15 Effect of pregnancy and preeclampsia on postnatal maternal cardiac function
B. Thilaganathan (London, UK)
- 15.30 Differences in the hemodynamic profile between preeclampsia and other forms of hypertension in pregnancy
C. Borghi (Bologna, IT)
- 15.45 Twin pregnancy and maternal cardiovascular function
T. Ghi (Bologna, IT)
- 16.00 Prepregnancy to early pregnancy changes in maternal cardiovascular physiology
A. Mahendru (Cambridge, UK - YIA)
- 16.10 Microvascular and macrovascular hemodynamic effects of nicardipine in the treatment of severe preeclampsia
J. Cornette (Rotterdam, NL)
- 16.20 Impaired mid gestational maternal cardiac function and left ventricular remodeling in women who subsequently develop preterm but not term preeclampsia
K. Melchiorre (London, UK)
- 16.30 Non invasive assessment of hemodynamics in early pregnancy
A.M. Van der Graaf (Groningen, NL - YIA)
- 16.40 Coffee Break

NUTRIENTS AND PREECLAMPSIA

Chair:

- F. Broughton Pipkin (Nottingham, UK), G. Di Renzo (Perugia, IT)
- 17.00 Antioxidants and preeclampsia
F. Broughton Pipkin (Nottingham, UK)
- 17.30 Chocolate, pregnancy and preeclampsia
G. Di Renzo (Perugia, IT)
- 17.45 How we might do without vitamins
F. Facchinetti (Modena, IT)
- 18.00 Role of nutrients in the risk of preeclampsia
A. M. Marconi (Milano, IT)

- 18.15 Placental FR- α and PCFT mRNA and protein expression are decreased in preeclampsia
P. Williams (Nottingham, UK - YIA)
- 18.25 Hypertension in pregnancy and endothelial dysfunction: an emerging risk factor for cardiovascular disease
G. Gagliardi (Roma, IT - YIA)
- 18.35 Endothelial function and glucose metabolism in overweight and obese nondiabetic woman: a possible role of L-Arginine/Nitric Oxide pathway.
E. Petrella (Modena, IT)
- Session ends

MATERNAL, FETAL, NEONATAL CRITICAL CARE

Chair: G. Zeeman (Groningen, NL), M. Lindheimer (Chicago, USA)

- 8.30 Short and long term neurological consequences of (pre) eclampsia
G. Zeeman (Groningen, NL)
- 9.00 Proteinuria and preeclampsia
M. Lindheimer (Chicago, USA)
- 9.30 Renal disease and preeclampsia
D. Manfellotto (Roma, IT)
- 9.45 Neonatal complications
V. Carnielli (Ancona, IT)
- 10.00 Redefinition of recurrence risk of preeclampsia
T. Frusca (Brescia, IT)
- 10.15 Uterine Doppler in Chronic hypertension as predictor of preeclampsia
P. Vergani (Milano, IT)
- 10.30 Kidney transplantation and pregnancy: maternal and fetal outcome
A. Ferreira (Coimbra, P - YIA)
- 10.40 Body liquids sectors of puerperal women with preeclampsia and their diagnostic role
G.N. Jonboboeva (Moscow, RUS)
- 10.50 Total vascular resistance and multigate spectral doppler analysis (MSDA) as a screening tool for preeclampsia. A pilot study
G. Tiralongo (Roma, IT - YIA)
- 11.00 Coffee break

MANAGEMENT AND RECOMMENDATIONS

Chair: J. Walker (Leeds, UK), C. Lees (Cambridge, UK)

- 11.15 Pre-eclampsia - the NICE Guidelines
J. Walker (Leeds, UK)
- 11.45 Drug development in pre-eclampsia
C. Lees (Cambridge, UK)
- 12.00 Severe preeclampsia: when to deliver?
C. Benedetto (Torino, IT)
- 12.15 Management of non severe early gestational hypertension
G.P. Novelli (Roma, IT)
- 12.30 Calcium antagonists in hypertensive disorders of pregnancy
S. Giannubilo (Ancona, IT)
- 12.45 Secondary preventive interventions of cardiovascular risk in women who had hypertension during pregnancy after 36 weeks gestation
F.V. Kesteren (Leiden, NL)
- 12.55 Effect of S nitroso glutathione GSNO on arterial wave reflection in severe early onset preeclampsia
T. Everett (Bristol, UK)
- 13.05 Is there any cardiovascular effect of carbetocin utilization that might prevent its use in preeclampsia? A TVR and CO study
I. Pisani (Roma, IT - YIA)
- 13.15 Lunch break

POSTER SESSION 2

Discussant: C. Lees (Cambridge, UK), P. Greco (Foggia, IT)

- 1. Clinical Utility of Uric Acid in the Detection of Preeclampsia in Hypertensive Pregnancy - Preliminary Results**
Campos S, Carvalho MJ, Raposo S, Bento N, Pais MSJ, Machado N, Moura P (Obstetrics Department of University Hospitals of Coimbra, Portugal)
- 2. Predictive value of the sFlt-1/PIGF ratio in pregnancies at risk for hypertensive disorders**
S. Husse, W. Schaarschmidt, A. Jank, B. Denk, H. Stepan (Leipzig, Penzberg, Germany)
- 3. Vascular Reactivity in Preeclampsia assessed using Finger tip hyperemia in a Rural African setting**
A. Meeme, A. Namugowa, G.A.B Buga, JE Iputo (Umtata, South Africa)
- 4. Association of augmentation index with uterine artery Doppler and risk of preeclampsia**
Everett TR, Mahendru AA, Wilkinson IB, Lees CC (Cambridge UK)
- 5. Risk factors for Pre-eclampsia, study in Iran**
Hamid Reza Baradaran (Tehran, Iran)
- 6. Did calcium management prevent preeclampsia?**
Sulovic Nenad, Kontic-Vucinic Olivera, Relic Goran, Sulovic Ljiljana (Belgrade, Serbia; Kosovska Mitrovica, Kosovo)
- 7. Uterine artery Doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, P-Selectin, NGAL) at 11+0 to 13+6 weeks in the prediction of late (>34 weeks) preeclampsia**
Antonio Farina, MD; Alessandra Curti, MD; Aly Youssef, MD; Giuseppina Rapacchia, MD; Francesca Righetti, MD; Giuliana Simonazzi, MD; Dalila Bernabini, MD; Nicola Rizzo, MD (Bologna, Italy) Supported in part by a PRIN project 2007 and RFO (to A.F. and N.R.)
- 8. Prepregnancy body mass index, weight gain and hypertensive disorders in pregnancy**
Cannata M. Letizia, Corrado F, Bucalo Me, Licata G, Interdonato MI, D'Anna R (Messina, Italy)
- 9. Hypertensive disorders in pregnant women affected by type 1 diabetes**
De Carolis S., Martino C., di Pasquo E., Santucci S., Stifani F., Macrì F., Degennaro V., Ferrazzani S. (Roma, Italy)
- 10. Association of aortic stiffness with uterine artery Doppler pulsatility index and risk of preeclampsia**
Thomas R. Everett, Amita A. Mahendru, Ian B. Wilkinson, Christoph C. Lees (Cambridge, United Kingdom)
- 11. Non-invasive haemodynamic monitoring using transthoracic echocardiography in pregnancy: validation against cardiac catheterisation**
Jerome Cornette, Hennie Iomgaard, Jolien Roos, Wim Hop, Robert C Pattinson (Pretoria, South Africa; Rotterdam, The Netherlands)
- 12. Pre-pregnancy cardiovascular risk in women with previous preeclampsia (PET)/intrauterine growth restriction (IUGR)**
Mahendru AA, Everett TR, McEniery CM, Wilkinson IB, Lees CC (Cambridge UK)
- 13. Increased maternal growth differentiation factor 15 in preeclampsia does not predict endothelial function 5-8 years postpartum**
Sugulle M, Kvehaugen AS, Dechend R, Staff AC (Oslo, Norway; Berlin, Germany)

14. **Comparison of Amino Terminal Pro Brain Natriuretic Peptide Levels in Hypertension Gestational Syndrome and Normotensive Pregnancy**
Authors and affiliation(s): Cabo Fustaret Marcela, Escobar Ana Maria, Illia Ricardo, Uranga Matias, Rivas Carlos, Olejnik Patricia. Lobenstein Guillermo, Camargo Alfredo (Buenos Aires, Argentina)
15. **Hellp Syndrome - Statistic of the department**
Marques C, Magalhães M, Carvalho M, Bento N, Pais SJ, Moura P (Coimbra, Portugal)
16. **Long term objective higher visual functioning and visionrelated quality of life following eclampsia**
Postma IR, Wiegman MJ, Ankersmit I, Roos NM, Zeeman GG, Bouma A (Groningen, The Netherlands)
17. **Hypertensive disorders in pregnancy and risk of severe mental disorders in the offspring in adulthood: The Helsinki Birth Cohort Study**
S. Tuovinen, K. Räikkönen, A.-K. Pesonen, M. Lahti, K. Heinonen, K. Wahlbeck, E. Kajantie, C. Osmond, D.J.P. Barker, J.G. Eriksson (Helsinki, Finland; Southampton, UK)
18. **Fathers with PTSD and depression in pregnancies complicated by preeclampsia or PPRM**
CAI Stramrood, M van Geenen, B Doornbos, JG Aarnoudse, PP van den Berg, WCM Weijmar Schultz, MG van Pampus (Groningen, The Netherlands)
19. **The effect of hypertensive disorders in pregnancy on quality of life post partum**
Ingrid A. Brussé MD, Ivette Meester, Eric A.P. Steegers MD PhD, A.J. Gerard, Jansen MD PhD, Gerhard H. Visser MD PhD, Johannes J. Duvekot MD PhD (Rotterdam, The Netherlands)
20. **Improving the quality of care using evidence-based approaches in hypertension in pregnancy: the role of audit to optimise clinical effectiveness**
Z.S. Khodzhaeva, A.M. Kholin, A.V. Nikolaeva (Moscow, Russia)
21. **TOTEM study (Temporise or Terminate pregnancy in women with severe preeclampsia at 28-34 weeks): a study protocol.**
J.J. Duvekot, E.A.P. Steegers, W.C.J. Hop1, A. Franx, J.A.M. van der Post, A. van Wassenaer, P. Dijk, E. van der Wilk, B.W. Mol on behalf of the TOTEM study collaboration group (Rotterdam, Utrecht, Amsterdam, Groningen, The Netherlands)
22. **The application of the electrolyte balanced hydroxyethylstarch solution -Tetraspan in complex infusion therapy of preeclampsia in perioperative care**
G.N. Jonboboeva, M. Torchinov, S.G. Tsakhilova, A.V. Pyregov, V.P. Kuznetsov (Moscow, Russia)
23. **Brain Injury on Pregnancy**
Santi, Wicaksono B., Sulistyono A., Dachlan EG (Surabaya, Indonesia)
24. **Do circulating angiogenic factors in pregnancies complicated by diabetes mellitus predict angiogenic factors and endothelial function postpartum?**
Anne Stine Kvehaugen, Meryam Sugulle, Anne Cathrine Staff (Oslo, Norway)
25. **Infant growth following a hypertensived pregnancy**
Green A., Loughna P., Broughton Pipkin F. (Nottingham, UK)

26. **Pregnancy stimulates cerebellar hemangioblastoma growth in von Hippel-Lindau disease**
C. Frantzen, R.C. Kruizinga, S.J. van Asselt, B.A. Zonnenberg, J.W.M. Lenders, W.W. de Herder, A.M.E. Walenkamp, R.H. Giles, F.J. Hes, W.J. Sluiter, T.P. Links, M.G. van Pampus
 (Groningen, Utrecht, Rotterdam, Amsterdam, The Netherlands)
27. **Age and parity as a risk factor for preeclampsia**
Azar Aghamohammadi (Sari, Iran)
28. **Association between trombophilia and preeclampsia**
Berks D, Duvekot J.J., Steegers EAP., Visser W.
 (Rotterdam, The Netherlands)
29. **Normotensive-Hypertensive pregnancy patterns among Pregnant women of Abstract Child bearing ages: a Chinese study**
Sosorburam , Bayarbat Baterdene, Hussain Tabish Wuhan, China
Ulan Bator, Mongolia

- 14.30 **PRESIDENTIAL LECTURE:**
Preeclampsia: not only a disease of pregnancy
B. Sibai (Cincinnati, US)
 Introduced by *A. Tranquilli (Ancona, IT)*

LONG TERM OUTCOMES

- Chair:** *M. Paidas (New Haven, USA), H. Valensise (Roma, IT)*
- 15.00 Maternal health consequences following pregnancies with placenta mediated complications
M. Paidas (New Haven, USA)
- 15.30 Pathophysiology and treatment of hypertension in women in the different phases of life
M.G. Modena (Modena, IT)
- 15.45 Echocardiographic markers of cardiovascular risk after placental related complications and cardiovascular outcome after a 4 years follow up
H. Valensise (Roma, IT)
- 16.00 Preeclampsia is associated to persistent long-term postpartum left ventricular myocardial injury
K. Melchiorre (London, UK)
- 16.10 Decreased vision related quality of life following eclampsia
M.J. Wiegman (Groningen, NL - YIA)
- 16.20 Hypertensive disorders in pregnancy and risk of severe mental disorders in the offspring in adulthood: The Helsinki Birth Cohort Study
S. Touvinen
(Helsinki, FIN - YIA)
- 16.30 Cardiovascular biomarkers during and after preeclamptic pregnancy
M. Sugulle (Oslo - NO)
- 16.45 **YOUNG INVESTIGATOR AWARD**
- 17.00 **CLOSING CEREMONY**
H. Valensise (Roma, IT), A. Tranquilli (Ancona, IT),
P. Greco (Foggia, IT)

REGISTRATION FEE

PRECONGRESS COURSE

ISSHP Member 100,00 EUR

ISSHP non Member 150,00 EUR

CONGRESS

ISSHP Member 400,00 EUR

(including ISSHP membership fee renewal)

ISSHP non Member 450,00 EUR

(including ISSHP membership fee)

Midwives, Residents and Students 250,00 EUR

PAYMENT

Payments can be made in EUR by bank transfer to:

Account name: Alfa congressi Srl

Account number: IT 09 B 02008 05285 000010626797

SWIFT: UNCRITM1P67

Bank: Unicredit Bank - Viale Angelico - Rome - Italy

Remember to state name of the participant and "ISSHP 2011" on all payments! If you require any other payment method please contact the organizers.

SEGRETERIA ORGANIZZATIVA



alfa congressi Srl

viale delle Milizie, 34 - 00192 Roma
tel. 063701121 r.a. - fax 063729067
info@alfaservice.com - www.alfaservice.com